MBX Biosciences, Inc. Common Stock
HealthcareNASDAQ:MBX · NASDAQ Global Select
-$1.74 today
Vol 2.16M · Avg 0.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.6%
avg 14.7%
ROIC
-26.5%
avg -39.3%
ROA
-22.6%
avg -35.6%
Analysis
ROA is currently the strongest return metric at -22.6% versus its period average of -35.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Peter Kent Hawryluk | Chief Executive Officer, President & Director | $992,775.00 | — | 57 | $727,667.00 | 2.17% |
Salomon Azoulay | Chief Medical Officer | $734,944.00 | — | 68 | $14,769.00 | 0.04% |
Steven L. Hoerter | Executive Chairperson | $40,477.00 | — | 55 | $12,500.00 | 0.04% |
Andreas Moraitis | Senior Vice President of Clinical Development | — | — | — | — | — |
Karen Basbaum | Chief Business Officer | — | — | — | — | — |
Michelle Graham | Chief Human Resources Officer | — | — | 59 | — | — |
Pete De Spain | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Chatan Charan | Senior Vice President of Pharmaceutical Development & Chemistry, Manufacturing and Controls | — | — | — | — | — |
John W. Smither | Interim Chief Financial Officer | — | — | 73 | $0.00 | <0.01% |
Michael A. Dorato DABT | Sr. Vice President of Discovery & Non-Clinical Development | — | — | — | — | — |
Mark Hope | Senior Vice President of Regulatory & Quality | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$13.06M
Sells
4
$2.71M
Net Sentiment
+$10.35M
Net buying
Most Active
Azoulay Salomon
3 transactions
Analysis
Insiders reported 4 buys worth $13.06M and 4 sells worth $2.71M over the last 12 months. That adds up to net buying of $10.35M. Azoulay Salomon was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Who manages MBX?
MBX Biosciences, Inc. Common Stock (MBX) lists 11 active executives. The top listed executive is Andreas Moraitis, Senior Vice President of Clinical Development.
Are MBX insiders buying or selling?
Recent insider activity shows net buying of $35.27M.
Explore More
Continue the stock analysis
Jump to another research area for this company.